JPH07309765A - Body fat accumulation suppressor - Google Patents
Body fat accumulation suppressorInfo
- Publication number
- JPH07309765A JPH07309765A JP10275994A JP10275994A JPH07309765A JP H07309765 A JPH07309765 A JP H07309765A JP 10275994 A JP10275994 A JP 10275994A JP 10275994 A JP10275994 A JP 10275994A JP H07309765 A JPH07309765 A JP H07309765A
- Authority
- JP
- Japan
- Prior art keywords
- fat
- body fat
- xylose
- arabinose
- accumulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
(57)【要約】 （修正有）
【構成】 Ｄ−キシロースおよび／またはＬ−アラビノ
ースを有効成分として含有する体脂肪蓄積抑制剤。
【効果】 上記の体脂肪（皮下脂肪、内臓脂肪）蓄積抑
制剤、体脂肪（皮下脂肪、内臓脂肪）減少剤を使用する
ことにより、体脂肪とくに内臓脂肪の蓄積が抑制され、
また内臓脂肪の減少効果が顕著になり、肥満、高血圧、
高脂血症等の健康障害を予防することができる。(57) [Summary] (Correction) [Structure] A body fat accumulation inhibitor containing D-xylose and / or L-arabinose as an active ingredient. [Effect] By using the above body fat (subcutaneous fat, visceral fat) accumulation suppressor and body fat (subcutaneous fat, visceral fat) reducer, accumulation of body fat, particularly visceral fat, is suppressed,
Moreover, the effect of reducing visceral fat becomes remarkable, and obesity, high blood pressure,
It is possible to prevent health disorders such as hyperlipidemia.
Description
【０００１】[0001]
【産業上の利用分野】この発明は体脂肪蓄積抑制剤に関
するものであり、詳細にはＤ−キシロースおよび／また
はＬ−アラビノースを有効成分とする体脂肪蓄積抑制
剤、体脂肪減少剤に関するものである。FIELD OF THE INVENTION The present invention relates to a body fat accumulation inhibitor, and more particularly to a body fat accumulation inhibitor and a body fat reducing agent containing D-xylose and / or L-arabinose as an active ingredient. is there.
【０００２】[0002]
【従来の技術】肥満は、高血圧、耐糖能異常、高脂血症
などを合併しやすく、虚血性心疾患、脳卒中、糖尿病な
どの危険因子と考えられており、成人病予防の観点か
ら、肥満対策はきわめて重要である。肥満とは、単に体
重が多いことではなく、体構成成分の内、脂肪組織の占
める割合（体脂肪率）が正常以上に増加した状態として
定義されている。そして近年、皮下脂肪、内臓脂肪等の
体脂肪の蓄積について、皮下組織にたまる皮下脂肪型肥
満よりも、臓器の間にたまる内臓脂肪型肥満の方が高血
圧、高脂血症、糖尿病などの成人病を合併しやすいこと
も報告されている。［徳永勝人・他：日本内科学会誌８
１巻 ９５−９９頁（１９９２年）。］この発明者等は
皮下脂肪、内臓脂肪等の体脂肪に対する各種薬剤の効果
を検討した所、Ｄ−キシロースおよび／またはＬ−アラ
ビノースに、体脂肪の蓄積を抑制する作用があるという
新知見を得、さらに鋭意研究を進めた結果、この発明を
完成した。BACKGROUND ART Obesity is easily associated with hypertension, impaired glucose tolerance, hyperlipidemia, etc., and is considered to be a risk factor for ischemic heart disease, stroke, diabetes, etc. Countermeasures are extremely important. Obesity is defined as a state in which the proportion of adipose tissue (body fat percentage) in body components is increased more than normal, rather than simply being heavy. In recent years, with regard to the accumulation of body fat such as subcutaneous fat and visceral fat, visceral fat obesity that accumulates between organs is more common in adults with hypertension, hyperlipidemia, diabetes, etc. than subcutaneous fat obesity that accumulates in subcutaneous tissues. It is also reported that the disease is likely to be complicated. [Katsuhito Tokunaga et al .: Journal of the Japanese Society of Internal Medicine 8
Volume 1, pages 95-99 (1992). The present inventors examined the effect of various drugs on body fat such as subcutaneous fat and visceral fat, and found that D-xylose and / or L-arabinose has a new effect of suppressing body fat accumulation. As a result of further earnest research, the present invention was completed.
【０００３】[0003]
【発明の構成】この発明は、Ｄ−キシロースおよび／ま
たはＬ−アラビノースを有効成分とする体脂肪蓄積抑制
剤、体脂肪減少剤を提供する。The present invention provides a body fat accumulation inhibitor and a body fat reducing agent containing D-xylose and / or L-arabinose as an active ingredient.
【０００４】この発明で使用するＤ−キシロースおよび
Ｌ−アラビノースは粉末、液状、結晶あるいは顆粒のい
ずれであってもよいし、米ヌカ、小麦フスマ、バガス
（さとうきびのしぼりかす）、とうもろこし外皮、綿実
殻等の加水分解物のＤ−キシロースおよびＬ−アラビノ
ース粗抽出物であってもよい。Ｄ−キシロースとＬ−ア
ラビノースを混合して使用する場合、両者の混合割合は
一般的には限定はないが、工業的には、例えば上記粗抽
出物を使用する場合、Ｄ−キシロースとＬ−アラビノー
スの割合は５０：５０ないし９９：１、好ましくは８
０：２０ないし９９：１の範囲が考えられる。The D-xylose and L-arabinose used in the present invention may be in the form of powder, liquid, crystals or granules, rice bran, wheat bran, bagasse (squeeze of sugar cane), corn rind and cotton. It may be a D-xylose and L-arabinose crude extract of a hydrolyzate such as a nut shell. When D-xylose and L-arabinose are used as a mixture, the mixing ratio of both is generally not limited, but industrially, for example, when the above crude extract is used, D-xylose and L-arabinose are mixed. The ratio of arabinose is 50:50 to 99: 1, preferably 8
A range of 0:20 to 99: 1 is possible.
【０００５】Ｄ−キシロースおよびＬ−アラビノースは
それぞれ単独あるいは両者を併用して体脂肪（皮下脂
肪、内臓脂肪）蓄積抑制剤として、体脂肪（皮下脂肪、
内臓脂肪）減少剤として使用することができる。これら
の用途で用いる場合には、例えばＤ−キシロース及び／
またはＬ−アラビノースの粉末、液状、結晶あるいは顆
粒をそのまま、あるいは水、エタノール、エチレングリ
コール、ポリエチレングリコール等の液状担体、澱粉、
セルロース、ポリアミド粉末等の固型担体等の無毒性担
体で希釈して、アンプル剤、顆粒剤、錠剤、丸剤、カプ
セル剤、シロップ剤等に常法にしたがって調製したもの
をＤ−キシロースおよび／またはＬ−アラビノースとし
て０．０１ｇ／ｋｇ以上投与するようにすればよい。D-xylose and L-arabinose may be used alone or in combination of both as body fat (subcutaneous fat, visceral fat) accumulation suppressors.
It can be used as a visceral fat) reducing agent. When used for these purposes, for example, D-xylose and / or
Alternatively, L-arabinose powder, liquid, crystals or granules as they are, or liquid carrier such as water, ethanol, ethylene glycol, polyethylene glycol, starch,
D-xylose and / or an ampoule, a granule, a tablet, a pill, a capsule, a syrup and the like prepared by diluting with a non-toxic carrier such as a solid carrier such as cellulose and polyamide powder Alternatively, 0.01 g / kg or more of L-arabinose may be administered.
【０００６】この発明の体脂肪蓄積抑制剤、体脂肪減少
剤は、上記のようにそれらを単独で人または動物に投与
することもできるが、一般の食品に添加して使用するこ
ともできる。例えば、Ｄ−キシロースおよび／またはＬ
−アラビノースを直接もしくは上記のような担体とを常
法に従って調製したものを各種食品、例えば清涼飲料
水、コーヒー、紅茶、果汁、牛乳、ジャム、あん、ゼリ
ー、菓子、コーンフレークなどの液状或いは固状の食
品、調味料、副食品等に添加して使用することもでき
る。The body fat accumulation suppressor and body fat reducer of the present invention can be administered alone to humans or animals as described above, or can be used by adding them to general foods. For example, D-xylose and / or L
-Arabinose prepared directly or with a carrier as described above according to a conventional method for various foods, such as soft drinks, coffee, tea, fruit juice, milk, jam, bean jam, jelly, confectionery, corn flakes, etc. It can also be used by adding it to foods, seasonings, side foods, etc.
【０００７】[0007]
【発明の効果】この発明の体脂肪（皮下脂肪、内臓脂
肪）蓄積抑制剤、体脂肪（皮下脂肪、内臓脂肪）減少剤
を使用することにより、体脂肪とくに内臓脂肪の蓄積が
抑制され、また内臓脂肪の減少効果が顕著になり、肥
満、高血圧、高脂血症等の健康障害を予防することがで
きる。The use of the body fat (subcutaneous fat, visceral fat) accumulation suppressor and body fat (subcutaneous fat, visceral fat) reducer of the present invention suppresses the accumulation of body fat, particularly visceral fat, and The visceral fat reducing effect becomes remarkable, and health disorders such as obesity, hypertension, and hyperlipidemia can be prevented.
【０００８】次にこの発明の効果を試験例により説明す
る。 試験例１ 内臓脂肪蓄積に対するキシロースの効果（ラット）：ラ
ット（ウイスター雄、６週令、体重約２１０ｇ）を１群
４匹とし、計１２匹使用した。飼料はＣＥ−２（日本ク
レア（株））（組成は下に示す通り）を使用し、１群
（対照）には、ＣＥ−２に砂糖２０％及びセルロース２
０％添加したものを与え、２群にはＣＥ−２に砂糖２０
％、セルロース１０％、Ｄ−キシロース１０％を添加し
たものを、３群にはＣＥ−２に砂糖２０％及びＤ−キシ
ロース２０％を添加したものを与えて、１０週間飼育し
た。飼育後屠殺・解剖し、副睾丸の周囲及び後腹膜の脂
肪をとりだし、重量を測定し、体重１００ｇ当りに補正
したものを脂肪率とした。結果は以下の通りである。Next, the effects of the present invention will be described with reference to test examples. Test Example 1 Effect of xylose on visceral fat accumulation (rat): Rats (male Wistar, 6-week-old, body weight: about 210 g) were made up of 4 rats per group, and 12 rats in total were used. CE-2 (CLEA Japan, Inc.) (composition as shown below) was used as the feed, and CE-2 had 20% sugar and 2 cellulose as a group (control).
0% added to the 2 groups CE-2 and sugar 20
%, Cellulose 10% and D-xylose 10% were added, and to group 3 were given CE-2 with 20% sugar and 20% D-xylose added, and were bred for 10 weeks. After rearing, the animals were slaughtered and dissected, and the fat around the epididymis and the retroperitoneum were taken out, weighed, and corrected for 100 g of body weight to obtain the fat percentage. The results are as follows.
【０００９】[0009]
【表１】 [Table 1]
【００１０】飼料組成： 水 分（％） ８．７ 粗 蛋 白 質（％） ２４．８ 粗 脂 肪（％） ４．４ 粗 繊 維（％） ３．５ 粗 灰 分（％） ７．０ 可溶性無窒素物（％） ５１．６Feed composition: Water (%) 8.7 Crude protein (%) 24.8 Crude fat (%) 4.4 Crude fiber (%) 3.5 Crude ash (%) 7. 0 Soluble nitrogen-free (%) 51.6
【００１１】試験例２ ラット（ウィスター、雄、８週令、体重約２９０ｇ）を
１群４匹とし、計１６匹使用した。飼料はＣＥ−２（日
本クレア（株））（組成は下に示す通り）を使用し、１
群（対照）には、ＣＥ−２に砂糖２０％及びセルロース
１０％添加したものを与え、２群にはＣＥ−２に砂糖２
０％及びＬ−アラビノース１０％を添加したものを、３
群にはＣＥ−２に砂糖２０％及びＤ−キシロース９％、
Ｌ−アラビノース１％を添加したものを、４群にはＣＥ
−２に砂糖２０％及びＤ−キシロース１０％添加したも
のを与え、４週間飼育した。飼育後屠殺、解剖し、内蔵
脂肪（副睾丸の周囲及び後腹膜、腸管膜の脂肪）と皮下
脂肪（腹部）を取り出し、重量を測定し、体重１００ｇ
当りに補正したものを、脂肪率とした。結果は以下の通
りである。 飼料組成： 水 分（％） ８．７ 粗 蛋 白 質（％） ２４．８ 粗 脂 肪（％） ４．４ 粗 繊 維（％） ３．５ 粗 灰 分（％） ７．０ 可溶性無窒素物（％） ５１．６Test Example 2 Rats (Wistar, male, 8 weeks old, weight: about 290 g) were made up of 4 rats per group, and 16 rats were used in total. The feed used was CE-2 (CLEA Japan, Inc.) (composition as shown below).
The group (control) was given CE-2 with 20% sugar and 10% cellulose added, and 2 groups were given CE-2 and sugar 2
Add 0% and L-arabinose 10% to 3
The group had CE-2 with 20% sugar and 9% D-xylose,
L-arabinose 1% was added to the 4 groups CE
-2 was added with 20% sugar and 10% D-xylose and fed for 4 weeks. After breeding, the animals are slaughtered and dissected, visceral fat (adipose around epididymis, retroperitoneum, and mesentery) and subcutaneous fat (abdomen) are taken out, weighed, and weighed 100 g.
The value corrected for the hit was defined as the fat percentage. The results are as follows. Feed composition: Water (%) 8.7 Crude protein (%) 24.8 Crude fat (%) 4.4 Crude fiber (%) 3.5 Crude ash (%) 7.0 Soluble Nitrogen (%) 51.6
【００１２】[0012]
【表２】 [Table 2]
Claims (2)
ビノースを有効成分として含有する体脂肪蓄積抑制剤。1. A body fat accumulation inhibitor containing D-xylose and / or L-arabinose as an active ingredient.
ビノースを有効成分として含有する体脂肪減少剤。2. A body fat reducing agent containing D-xylose and / or L-arabinose as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10275994A JPH07309765A (en) | 1994-05-17 | 1994-05-17 | Body fat accumulation suppressor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10275994A JPH07309765A (en) | 1994-05-17 | 1994-05-17 | Body fat accumulation suppressor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH07309765A true JPH07309765A (en) | 1995-11-28 |
Family
ID=14336132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10275994A Pending JPH07309765A (en) | 1994-05-17 | 1994-05-17 | Body fat accumulation suppressor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH07309765A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0724842A3 (en) * | 1994-12-15 | 1997-02-12 | Antonio Picarelli | Preparation for the treatment of obesity |
| WO2000044754A1 (en) * | 1999-01-29 | 2000-08-03 | Sumitomo Chemical Company, Limited | Fat accumulation inhibitory agents |
| JP2002154967A (en) * | 2000-11-15 | 2002-05-28 | Makoto Fujii | Diabetes treatment |
| EP1167536A4 (en) * | 2000-02-01 | 2005-08-03 | Unitika Ltd | Process for producing l-arabinose, l-arabinose-containing enzymatically processed products, diet foods, diabetic diet foods and fruit or vegetable juices and process for producing the same |
| US8071141B2 (en) | 2000-12-12 | 2011-12-06 | Kaneka Corporation | Compositions for preventing or ameliorating multiple risk factor syndromes |
| JP2013172711A (en) * | 2012-01-26 | 2013-09-05 | Kanazawa Inst Of Technology | Antioxidant composition, composition inhibiting activity of disaccharide hydrolase, composition for intestinal regulation, diet composition, food and drink, and method of selectively producing arabinose |
-
1994
- 1994-05-17 JP JP10275994A patent/JPH07309765A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0724842A3 (en) * | 1994-12-15 | 1997-02-12 | Antonio Picarelli | Preparation for the treatment of obesity |
| WO2000044754A1 (en) * | 1999-01-29 | 2000-08-03 | Sumitomo Chemical Company, Limited | Fat accumulation inhibitory agents |
| EP1167536A4 (en) * | 2000-02-01 | 2005-08-03 | Unitika Ltd | Process for producing l-arabinose, l-arabinose-containing enzymatically processed products, diet foods, diabetic diet foods and fruit or vegetable juices and process for producing the same |
| JP2002154967A (en) * | 2000-11-15 | 2002-05-28 | Makoto Fujii | Diabetes treatment |
| US8071141B2 (en) | 2000-12-12 | 2011-12-06 | Kaneka Corporation | Compositions for preventing or ameliorating multiple risk factor syndromes |
| JP2013172711A (en) * | 2012-01-26 | 2013-09-05 | Kanazawa Inst Of Technology | Antioxidant composition, composition inhibiting activity of disaccharide hydrolase, composition for intestinal regulation, diet composition, food and drink, and method of selectively producing arabinose |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5607397B2 (en) | Composition for preventing or ameliorating multiple risk factor syndrome | |
| US8648040B2 (en) | Amino acid composition for improving glucose tolerance | |
| JPH067117A (en) | Inhibitor of diet lipid digestive absorption and food/ beverage containing the same | |
| EP2625968A1 (en) | Composition and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety | |
| US20180264020A1 (en) | Composition for prevention, amelioration or treatment of metabolic syndrome | |
| US8722614B2 (en) | Adiponectin production enhancer | |
| JPH07242551A (en) | Body fat accumulation suppressor | |
| JP2009286703A (en) | Body fat accumulation-improving agent and metabolic syndrome-improving agent containing d-tagatose as active ingredient | |
| WO1994012057A1 (en) | Diet sweetener | |
| WO2007142230A1 (en) | Lipid-metabolism-improving agent | |
| JP2012001516A (en) | Composition containing coix seed protein having lipid/carbohydrate metabolism improving action | |
| JPH11180869A (en) | Blood lipid improving agent, cyclic amp phosphodiesterase inhibitor, drink and food, and skin preparation for external use | |
| TWI465245B (en) | Peptides with antidiabetic effect and their use | |
| US20060034781A1 (en) | Peroral preparation for prevention or treatment of atopic dermatatis | |
| WO2002055073A1 (en) | Preventives for arthritis | |
| JPH05186356A (en) | Diet lipid digestive absorption inhibitor and food/ beverage containing the same | |
| JP5158779B2 (en) | Antihypertensive agent comprising D-allose as an active ingredient | |
| JPH11147828A (en) | Cholesterol and lipid absorption inhibitors | |
| JP3234113B2 (en) | Blood glucose elevation inhibitors and uses | |
| JPS60186261A (en) | Solid food composition | |
| JP2012162472A (en) | Lipid eliminant | |
| JPWO2008111651A1 (en) | Metabolic syndrome improving or preventing agent, and beverage, food and feed containing the same | |
| JP3345650B2 (en) | Hypertension inhibitor | |
| JP2008231080A (en) | Leptin secretion promoter from adipocytes | |
| JP2003261445A (en) | Blood neutral fat reducing agent |